Telomerase inhibition in haematological neoplasms—are we ready for primetime?

Mrinal M. Patnaik

doi:10.1016/S0140-6736(23)02187-6

Telomerase inhibition in haematological neoplasms—are we ready for primetime?

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	220-222
Number of pages	3
Journal	The Lancet
Volume	403
Issue number	10423
DOIs	https://doi.org/10.1016/S0140-6736(23)02187-6
State	Published - Jan 20 2024

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(23)02187-6

Cite this

@article{ddcac575bcfa4af7862a4550e4360978,

title = "Telomerase inhibition in haematological neoplasms—are we ready for primetime?",

author = "Patnaik, {Mrinal M.}",

year = "2024",

month = jan,

day = "20",

doi = "10.1016/S0140-6736(23)02187-6",

language = "English (US)",

volume = "403",

pages = "220--222",

journal = "The Lancet",

issn = "0140-6736",